General Information
Azacitidine is used to treat myelodysplastic syndromes (MDS), a number of disorders in which not enough healthy blood cells are produced in the bone marrow, leaving patients with low blood counts. In healthy bone marrow, stem cells become red blood cells, white blood cells or platelets. In MDS, this process is dysfunctional. In a significant portion of patients, MDS progresses to a rapidly growing cancer of bone marrow cells called acute myeloid leukemia.
About the API
- Japan DMF
- Korea DMF
- US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.